Naveed Sattar
A5078498803- Diabetes Treatment and Management
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Lipoproteins and Cardiovascular Health
- Genetic Associations and Epidemiology
- Diabetes Management and Research
- Diet and metabolism studies
- Birth, Development, and Health
- Cardiovascular Function and Risk Factors
- Metabolism, Diabetes, and Cancer
- Adipokines, Inflammation, and Metabolic Diseases
- Liver Disease Diagnosis and Treatment
- Obesity, Physical Activity, Diet
- Heart Failure Treatment and Management
- Gestational Diabetes Research and Management
- Nutritional Studies and Diet
- Pancreatic function and diabetes
- Pregnancy and preeclampsia studies
- Chronic Disease Management Strategies
- Obesity and Health Practices
- Bariatric Surgery and Outcomes
- Cardiovascular Disease and Adiposity
- Blood Pressure and Hypertension Studies
- COVID-19 Clinical Research Studies
- Nutrition and Health in Aging
- Rheumatoid Arthritis Research and Therapies
British Heart Foundation
2016-2025
University of Glasgow
2016-2025
Glasgow Royal Infirmary
2006-2025
NHS Greater Glasgow and Clyde
2007-2025
Louis Stokes Cleveland VA Medical Center
2022-2025
Case Western Reserve University
2025
Imperial College London
2012-2024
University College London
2010-2024
Nuffield Health
2024
National Health and Medical Research Council
2024
ABI : ankle–brachial (blood pressure) index ABPM : ambulatory blood pressure monitoring ACCORD : Action to Control Cardiovascular Risk in Diabetes ACE-I : angiotensin-converting enzyme inhibitor ACS : acute coronary syndromes ADVANCE : Diabetes and Vascular disease: PreterAx
The ESC Guidelines represent the views of and were produced after careful consideration scientific medical knowledge evidence available at time their publication.The is not responsible in event any contradiction, discrepancy and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies.Health professionals are encouraged take fully into account when exercising clinical...
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless presence or absence diabetes. More evidence is needed regarding effects these drugs across broad spectrum failure, including those with a markedly reduced ejection fraction.
Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with and a reduced ejection fraction, but their effects preserved fraction are uncertain.
The extent to which diabetes mellitus or hyperglycemia is related risk of death from cancer other nonvascular conditions uncertain.
with the European Association for Study of Diabetes (EASD).
The National Cholesterol Education Program (NCEP) recently proposed a simple definition for metabolic syndrome. Information on the prospective association of this coronary heart disease (CHD) and type 2 diabetes is currently limited.We used modified NCEP with body mass index in place waist circumference. Baseline assessments West Scotland Coronary Prevention Study were available 6447 men to predict CHD risk 5974 incident over 4.9 years follow-up. Mean LDL cholesterol was similar but...
Objectives: To develop evidence-based EULAR recommendations for cardiovascular (CV) risk management in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic (PsA). Methods: A multidisciplinary expert committee was convened as a task force of the Standing Committee Clinical Affairs (ESCCA), comprising 18 members including rheumatologists, cardiologists, internists epidemiologists, representing nine European countries. Problem areas related keywords systematic...
Patients with diabetes are at higher risk for death and cardiovascular outcomes than the general population. We investigated whether excess of events among patients type 2 could be reduced or eliminated.
Long-term trends in excess risk of death and cardiovascular outcomes have not been extensively studied persons with type 1 diabetes or 2 diabetes.We included patients registered the Swedish National Diabetes Register from 1998 through 2012 followed them 2014. Trends deaths events were estimated Cox regression standardized incidence rates. For each patient, controls who matched for age, sex, county randomly selected general population.Among diabetes, absolute changes during study period rates...
There is debate about the value of assessing levels C-reactive protein (CRP) and other biomarkers inflammation for prediction first cardiovascular events.We analyzed data from 52 prospective studies that included 246,669 participants without a history disease to investigate adding CRP or fibrinogen conventional risk factors risk. We calculated measures discrimination reclassification during follow-up modeled clinical implications initiation statin therapy after assessment fibrinogen.The...